AlgenBrain AI meets CRISPR for rapid, scaled decoding of cellular networks, uncovering effective intervention points through disease trajectory reverse engineering

Problem

Diseases are progressive.

The ways we do drug discovery are not.

Problem Diseases

The Status Quo

Other CRIPR-based platforms
  • Close
    Crude phenotypes
  • Close
    Lack of clinically relevant endpoints
  • Close
    Labor intensive target prioritization
Other AI-based platforms
  • Close
    Built on correlation
  • Close
    Image-based phenotyping
  • Close
    No direct biological validation
Solution

We unravel complex biology using precision gene modulation to pinpoint causal signaling pathways that reverse the molecular landscape of disease progression, illuminating routes to novel therapeutics

Solution
Drug disovery partners
Pfizer
Nvidia
Berkeley
MSKCC
UCSF
NIH

Our breakthrough is fueled by proprietary CRISPR and AI to redefine the boundaries of disease understanding at unparalleled precision and scale

Built from bottom to top on human biology to accelerate therapeutics to clinic
CRISPR data creation at scale
  • Check Icon
    Proprietary AlgenCRISPR Gene Modulation System.
  • Check Icon
    Generate fit-for-purpose, single-cell RNA sequencing data at scale.
  • Check Icon
    End-to-end in-house wet lab expertise.
Line
1
Therapeutic Insights
Innovation spanning the breadth of drug discovery
  • Check Icon
    First-in-class target / biology
  • Check Icon
    Best-in-class drug / MoA
  • Check Icon
    Patient relevant disease modeling
Line
3
CRISPR data learning at scale
  • Check Icon
    Proprietary foundational models for disease trajectory mapping in latent space.
  • Check Icon
    Decode casual mechanisms driving cell fate via quantifying CRISPR-modulated cell fates and mRNA + non-coding RNA interrogation.
Line
2

Values we bring

Crispr Data
CRISPR data creation and learning at scale

Robust and repeatable processes and ever-growing CRISPR modulation data universe poised to elucidate impactful disease biology across multiple indications

Translatability
Translatability from bench to bedside

From first-in-class, human-centric discovery to best-in-class drug development, actionable therapeutic insights derived from our technology offer unprecedented depth to maximize translatability and drug therapeutic index

Precision Medicine
Precision
Medicine

Our high-resolution disease context delineates the full landscape of disease severity and cell states, revealing effective intervention points for stage-specific and cell type-specific precision targets

Enabling end to end technology solutions

We are leveraging AlgenCRISPR and AI to redefine possibilities in biology across drug discovery value chain
Disease

Disease Modeling

Quantify and improve clinical relevance of in vitro models to translate discovery from bench to bedside

Target

Target

Novel, high-confidence targets to reverse casual disease progression

Molecule

Molecule

On-target and safe drug candidates matching desired patient response profile

Clinical Translation
Clinical Translation

Indication focus

Therapeutic Area
Indications
Target Discovery
Lead Discovery
Preclinical
Clinical
Precision Oncology
Solid Tumors
Immunology
Autoimmune & Inflammation

Partner with us

Together, we transform the future of medicine

Discover Partnerships

Contact Us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.